Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype. 2022

Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
School of Health & Biomedical Sciences, RMIT University, Bundoora, Australia.

Programmed death-ligand 1 (PD-L1) copy number gains may be predictive of clinical response to immunotherapy in NSCLC. This study investigated PD-L1 copy number variations in tumor resection and bronchoscopy biopsies and its relationship with PD-L1 tumor cell staining and inflammatory gene expression. PD-L1 gene copy number and mRNA expression were evaluated by real-time polymerase chain reaction in surgically resected NSCLC tumor biopsies (n = 87) and control biopsies (n = 20). A second cohort (n = 15) of bronchoscopy-derived tumor biopsies was analyzed, including multiple biopsies from the same patient across different anatomical sites. PD-L1 mRNA levels strongly correlated with PD-L1 tumor staining (r = 0.55, p < 0.0001). Interferon-γ mRNA expression associated with PD-L1 immune cell staining, but not PD-L1 tumor cell staining. In contrast, PD-L1 copy number positively associated PD-L1 tumor staining, but not PD-L1 immune cell staining. PD-L1 copy number analysis detected loss (15 of 87 = 17%) and gain (5 of 87 = 7%) of copy number. Tumors with low PD-L1 copy number expressed significantly reduced levels of inflammatory (interferon-γ, interleukin [IL]-6, IL-1β, MMP-9) and immunosuppressive (IL-10, transforming growth factor β) mediators. Analysis of bronchoscopy-derived biopsies revealed low heterogeneity in copy number values across different anatomical sites, in contrast to more variable PD-L1 mRNA expression. Low PD-L1 copy number tumors display reduced PD-L1 expression, reduced PD-L1 tumor cell staining, and an immunologic cold tumor microenvironment. Because PD-L1 copy number values are highly stable across different tumor regions, its evaluation may represent a robust and complimentary biomarker for predicting response to immunotherapy, where low copy number may predict lack of response.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013194 Staining and Labeling The marking of biological material with a dye or other reagent for the purpose of identifying and quantitating components of tissues, cells or their extracts. Histological Labeling,Staining,Histological Labelings,Labeling and Staining,Labeling, Histological,Labelings, Histological,Stainings
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D056915 DNA Copy Number Variations Stretches of genomic DNA that exist in different multiples between individuals. Many copy number variations have been associated with susceptibility or resistance to disease. Copy Number Polymorphism,DNA Copy Number Variant,Copy Number Changes, DNA,Copy Number Polymorphisms,Copy Number Variants, DNA,Copy Number Variation, DNA,DNA Copy Number Change,DNA Copy Number Changes,DNA Copy Number Polymorphism,DNA Copy Number Polymorphisms,DNA Copy Number Variants,DNA Copy Number Variation,Polymorphism, Copy Number,Polymorphisms, Copy Number
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D060890 B7-H1 Antigen An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION. Antigens, CD274,PD-L1 Protein,Programmed Cell Death 1 Ligand 1 Protein,Programmed Death Ligand 1,B7-H1 Immune Costimulatory Protein,B7H1 Immune Costimulatory Protein,CD274 Antigen,PD-L1 Costimulatory Protein,Programmed Cell Death 1 Ligand 1,Antigen, B7-H1,Antigen, CD274,B7 H1 Antigen,B7 H1 Immune Costimulatory Protein,CD274 Antigens,Costimulatory Protein, PD-L1,PD L1 Costimulatory Protein,PD L1 Protein

Related Publications

Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
July 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
September 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
May 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
April 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
February 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
December 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
September 2019, Cancers,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
September 2019, Chronic diseases and translational medicine,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
December 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Savreet Aujla, and Christian Aloe, and Amanda Vannitamby, and Shona Hendry, and Kanishka Rangamuwa, and Hao Wang, and Ross Vlahos, and Stavros Selemidis, and Tracy Leong, and Daniel Steinfort, and Steven Bozinovski
February 2022, JTO clinical and research reports,
Copied contents to your clipboard!